169 related articles for article (PubMed ID: 9858908)
1. Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-alpha.
Tzai TS; Shiau AL; Wu CL; Chow NH; Tsai YS
Anticancer Res; 1998; 18(5A):3355-61. PubMed ID: 9858908
[TBL] [Abstract][Full Text] [Related]
2. Postoperative administration of interleukin-12 significantly enhances the anti-tumor immune response of MBT-2 bladder cancer bearing mice.
Tzai TS; Shiau AL; Wu CL; Tsai YS
Proc Natl Sci Counc Repub China B; 2000 Apr; 24(2):56-62. PubMed ID: 10809081
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the immunostimulating effect of autologous tumor vaccine by anti-TGF-beta antibody and interferon-alpha on murine MBT-2 bladder cancer.
Tzai TS; Shiau AL; Lin CS; Wu CL; Lin JS
Anticancer Res; 1997; 17(2A):1073-8. PubMed ID: 9137451
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes.
Tzai TS; Lin SN
J Urol; 1992 Feb; 147(2):523-7. PubMed ID: 1732635
[TBL] [Abstract][Full Text] [Related]
5. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
[TBL] [Abstract][Full Text] [Related]
6. Cytokine gene modification of bladder cancer cells for the establishment of bladder cancer vaccine.
Saito S; Tazaki H; Heston WD; Fair WR
Int J Urol; 1996 Jan; 3(1 Suppl):S35-9. PubMed ID: 24304018
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
9. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
10. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
Wang Z; Cheng Y; Zheng R; Qin D; Liu G
Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
12. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
13. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
15. Experimental study of the efficacy of combined use of cancer vaccine and interferon.
Potebnya GP; Kudryavets YY; Lisovenko GS; Cheremshenko NL; Voeykova IM; Trokhimenko NV; Symchich TV; Evstrateyva LM
Exp Oncol; 2007 Jun; 29(2):102-5. PubMed ID: 17704740
[TBL] [Abstract][Full Text] [Related]
16. Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy.
Kadhim SA; Chin JL
Urol Res; 1991; 19(1):57-62. PubMed ID: 1674182
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
Lee CF; Chang SY; Hsieh DS; Yu DS
J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
[TBL] [Abstract][Full Text] [Related]
18. Antitumor mechanism of recombinant murine interleukin-12 vaccine.
Yin X; Yan X; Yang Q; Cao H; Liang H
Cancer Biother Radiopharm; 2010 Jun; 25(3):263-8. PubMed ID: 20578831
[TBL] [Abstract][Full Text] [Related]
19. Construction of recombinant human IFNα-2b BCG and its antitumor effects on bladder cancer cells in vitro.
Sun E; Nian X; Liu C; Fan X; Han R
Genet Mol Res; 2015 Apr; 14(2):3436-49. PubMed ID: 25966110
[TBL] [Abstract][Full Text] [Related]
20. Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study.
Natsis K; Toliou T; Stravoravdi P; Kirtsis P; Grekou A; Barich A; Konstantinidis E; Gigis P
Int J Clin Pharmacol Res; 1997; 17(1):31-6. PubMed ID: 9403351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]